Staff in pharmaceutical jobs
at Pfizer are to commit to a new focus on rare diseases with the creation of a new dedicated research unit.
The multinational company has formed a rare diseases research unit within its Worldwide Research and Development division, which will focus on discovering treatments for conditions affecting fewer than 200,000 people.
More than 6,000 of these orphan diseases are currently classified, with in excess of 90 per cent of these conditions presently having no identified treatments which address their root cause.
Dr Jose Carlos Gutierrez-Ramos, senior vice-president of biotherapeutics research and development for Pfizer, expressed confidence that the new unit will be able to cater to unmet medical needs.
He said: "We are coupling Pfizer's existing experience in rare diseases, such as haemophilia, with our advanced protein technologies, resources and world-class scientific team to focus on becoming a driving force in rare disease research."
This comes after Pfizer reorganised its Worldwide Research and Development division last month to fully integrate the research and drug development
functions acquired in the recent merger with Wyeth.